Don M Benson, MD, PhD

College

College of Medicine

Department/Division

Internal Medicine

Academic Title

Professor-Clinical

Research Program

Molecular Carcinogenesis and Chemoprevention

Research Interest

Multiple Myeloma, Cancer, Lymphoma, Non-Hodgkin, Graft vs Host Disease, Amyloidosis, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Fatigue, Leukemia, Myeloid, Acute, Melanoma

Don Benson Jr., MD PhD, FACP, is a member of the Molecular Carcinogenesis and Chemoprevention Program at the OSUCCC – James, where he and his multidisciplinary, subspecialized team care for patients with multiple myeloma and amyloidosis, as well as those undergoing blood and marrow stem cell transplantation.

Following his internal medicine residency at the University of Virginia, Dr. Benson came to The Ohio State University to complete his subspecialty training in clinical oncology and his postdoctoral laboratory training. He joined the faculty at Ohio State in 2006 and holds the rank of associate professor of medicine. He is ABIM board certified in medical oncology and holds a Fellowship in the American College of Physicians.

Dr. Benson also serves as the interim director of the Division of Hematology, as well as the division’s head of translational research, where he helps facilitate the connection of new laboratory discoveries to clinical trials for patients with cancer. His research interests are focused in the development of immune-based therapy for multiple myeloma and other cancers.

Work by his laboratory team has helped bring new immune-based and targeted therapies to clinical use. In addition to laboratory-based research, Dr. Benson has led over 100 therapeutic clinical trials as principal or co-principal investigator in which he has tested promising novel treatments for cancer. His team has published over 90 peer-reviewed research manuscripts in the most eminent journals of the field, and they have presented their research findings in over 100 abstracts and presentations at scientific meetings around the world.

Dr. Benson is also involved in Ohio State’s medical education mission and has received both the Professor of the Year Award (2012) and the Distinguished Educator Award (2016) from The Ohio State University College of Medicine.

Education

BA, Wheeling Jesuit College

Wheeling, WV (USA)
Fellowship, The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Columbus, OH (USA)
Fellowship, The Ohio State University College of Medicine

Columbus, OH (USA)
Fellowship, The Ohio State University College of Medicine

Columbus, OH (USA)

Residencies

Chief Medical Resident & Instructor of Clinical Internal Medicine

University of Virginia School of Medicine

Charlottesville, VA (USA)
Intern and Resident, Internal Medicine

University of Virginia Health Sciences Center

Charlottesville, VA (USA)

Fellowship

Assistant Professor of Medicine and Coordinator of Education Division of Hematology, Department of Internal Medicine

The Ohio State University College of Medicine

Columbus, OH (USA)
Associate Professor of Medicine and Coordinator of Education, Division of Hematology, Department of Internal Medicine

The Ohio State University College of Medicine

Columbus, OH (USA)
Clinical Instructor – Housestaff, Division of Hematology/Oncology Department of Medicine, and Postdoctoral Fellow

The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Columbus, OH (USA)

Office Location

A445 Starling Loving Hall

320 W 10th Ave, Columbus, OH 43210

614-366-3802

614-293-7526

benson.236@osu.edu;DON.BENSON@OSUMC.EDU

Publications

Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant.

Wildes TM, Hofmeister C, Jaglowski S, Efebera YA, Jones D, Devine S, Huang Y, Benson DM, Naughton MJ, Dyko A, Byrd JC, Bhatt G, Rosko AE, Burd CE

J Geriatr Oncol in press 07/05/2018
Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia.

Buteyn NJ, Fatehchand K, Harrington BK, Henderson SE, Benson DM, Tridandapani S, Butchar JP, Dettorre GM, Byrd JC, Merchand-Reyes G, Santhanam R, Fang H, Carson WE, Vasu S, Gautam S, Mo X

Int Immunol in press 06/02/2018
A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma.

Benson DM, Barrett ER, Kang S, Youssef Y, Glankler EN, Ahmed EH, Zhang J, Carter AM, Caligiuri MA, Yu J, Chen L, Chan WK, Prasad A

Cancer Immunol Res in press 05/16/2018
Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo Expanded Autologous NK Cells.

Zhang J, Wang Y, Caligiuri MA, Zhang Y, Hughes T, Benson DM, Yu J

Clin Cancer Res in press 04/17/2018
Ninety-minute daratumumab infusion is safe in multiple myeloma.

Rosko AE, Efebera YA, Hofmeister CC, Benson DM, Sharma N, Williams N, Waller A, Barr H, Dempsey J, Huang Y

Leukemia in press 03/31/2018
Psychosocial risk predicts high readmission rates for hematopoietic cell transplant recipients.

Elder P, McGinty HL, Benson D, Huang Y, Devine S, Andritsos L, Vasu S, Richardson DR, Jaglowski S, Hofmeister C, Kirkendall C, Newlin J, Efebera Y, William B, Rosko AE, Penza S, Blum W, Klisovic R

Bone Marrow Transplant in press 02/14/2018
A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.

Sborov DW, Canella A, Hade EM, Mo X, Khountham S, Wang J, Ni W, Poi M, Coss C, Liu Z, Phelps MA, Mortazavi A, Andritsos L, Baiocchi RA, Christian BA, Benson DM, Flynn J, Porcu P, Byrd JC, Pichiorri F, Hofmeister CC

Leuk Lymphoma 58 2310-2318 10/01/2017
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.

Martin T, Baz R, Benson DM, Lendvai N, Wolf J, Munster P, Lesokhin AM, Wack C, Charpentier E, Campana F, Vij R

Blood 129 3294-3303 06/22/2017
Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial.

Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, Gao Y, Tackett K, Williams N, Benson DM, Efebera YA, Rosko AE, Devine SM, Poi M, Hofmeister CC, Phelps MA, Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, Gao Y, Tackett K, Williams N, Benson DM, Efebera YA, Rosko AE, Devine SM, Poi M, Hofmeister CC, Phelps MA

Clin Pharmacol Ther 012 511-19 02/04/2017
Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial.

Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, Gao Y, Tackett K, Williams N, Benson DM, Efebera YA, Rosko AE, Devine SM, Poi M, Hofmeister CC, Phelps MA, Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, Gao Y, Tackett K, Williams N, Benson DM, Efebera YA, Rosko AE, Devine SM, Poi M, Hofmeister CC, Phelps MA

Clin Pharmacol Ther 012 511-19 02/04/2017
Checkpoint inhibition in myeloma.

Benson DM Jr, Benson DM

Hematology Am Soc Hematol Educ Program 2016 528-533 12/02/2016
Checkpoint inhibition in myeloma.

Benson DM Jr, Benson DM

Hematology Am Soc Hematol Educ Program 2016 528-533 12/02/2016
Interferon-? Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells.

Fatehchand K, McMichael EL, Reader BF, Fang H, Santhanam R, Gautam S, Elavazhagan S, Mehta P, Buteyn NJ, Merchand-Reyes G, Vasu S, Mo X, Benson DM, Blachly JS, Carson WE 3rd, Byrd JC, Butchar JP, Tridandapani S, Fatehchand K, McMichael EL, Reader BF, Fang H, Santhanam R, Gautam S, Elavazhagan S, Mehta P, Buteyn NJ, Merchand-Reyes G, Vasu S, Mo X, Benson DM Jr, Blachly JS, Carson WE, Byrd JC, Butchar JP, Tridandapani S

J Biol Chem 291 25656-25666 12/02/2016
Interferon-? Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells.

Fatehchand K, McMichael EL, Reader BF, Fang H, Santhanam R, Gautam S, Elavazhagan S, Mehta P, Buteyn NJ, Merchand-Reyes G, Vasu S, Mo X, Benson DM, Blachly JS, Carson WE 3rd, Byrd JC, Butchar JP, Tridandapani S, Fatehchand K, McMichael EL, Reader BF, Fang H, Santhanam R, Gautam S, Elavazhagan S, Mehta P, Buteyn NJ, Merchand-Reyes G, Vasu S, Mo X, Benson DM Jr, Blachly JS, Carson WE, Byrd JC, Butchar JP, Tridandapani S

J Biol Chem 291 25656-25666 12/02/2016
Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy.

Vasu S, Wu H, Satoskar A, Puto M, Roddy J, Blum W, Klisovic R, Andritsos L, Hofmeister C, Benson DM, Efebera Y, Jaglowski S, Penza S, Cohen D, Devine S, Cataland S

Bone Marrow Transplant 51 1241-4 09/01/2016
Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development.

Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM, Hofmeister C, Alder H, Garofalo M, Di Leva G, Volinia S, Lin HJ, Perrotti D, Kuehl M, Aqeilan RI, Palumbo A, Croce CM, Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM Jr, Hofmainster C, Alder H, Garofalo M, Di Leva G, Volinia S, Lin HJ, Perrotti D, Kuehl M, Aqeilan RI, Palumbo A, Croce CM

Cancer Cell 30 349-351 08/08/2016
Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development.

Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM, Hofmeister C, Alder H, Garofalo M, Di Leva G, Volinia S, Lin HJ, Perrotti D, Kuehl M, Aqeilan RI, Palumbo A, Croce CM, Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM Jr, Hofmainster C, Alder H, Garofalo M, Di Leva G, Volinia S, Lin HJ, Perrotti D, Kuehl M, Aqeilan RI, Palumbo A, Croce CM

Cancer Cell 30 349-351 08/08/2016
Erratum to "Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease" [Biol Blood Marrow Transplant 22(2016):658-668].

Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, O'Donnell LC, Bradbury H, Kitzler R, Andritsos L, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Benson DM, Muthusamy N, Lozanski G, Devine SM

Biol Blood Marrow Transplant 22 1341 07/01/2016
Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma.

Stiff A, Caserta E, Sborov DW, Nuovo GJ, Mo X, Schlotter SY, Canella A, Smith E, Badway J, Old M, Jaime-Ramirez AC, Yan P, Benson DM, Byrd JC, Baiocchi R, Kaur B, Hofmeister CC, Pichiorri F, Stiff A, Caserta E, Sborov DW, Nuovo GJ, Mo X, Schlotter SY, Canella A, Smith E, Badway J, Old M, Jaime-Ramirez AC, Yan P, Benson DM Jr, Byrd JC, Baiocchi R, Kaur B, Hofmeister CC, Pichiorri F, Stiff A, Caserta E, Sborov DW, Nuovo GJ, Mo X, Schlotter SY, Canella A, Smith E, Badway J, Old M, Jaime-Ramirez AC, Yan P, Benson DM, Byrd JC, Baiocchi R, Kaur B, Hofmeister CC, Pichiorri F

Mol Cancer Ther 15 830-41 05/01/2016
Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma.

Stiff A, Caserta E, Sborov DW, Nuovo GJ, Mo X, Schlotter SY, Canella A, Smith E, Badway J, Old M, Jaime-Ramirez AC, Yan P, Benson DM, Byrd JC, Baiocchi R, Kaur B, Hofmeister CC, Pichiorri F, Stiff A, Caserta E, Sborov DW, Nuovo GJ, Mo X, Schlotter SY, Canella A, Smith E, Badway J, Old M, Jaime-Ramirez AC, Yan P, Benson DM Jr, Byrd JC, Baiocchi R, Kaur B, Hofmeister CC, Pichiorri F, Stiff A, Caserta E, Sborov DW, Nuovo GJ, Mo X, Schlotter SY, Canella A, Smith E, Badway J, Old M, Jaime-Ramirez AC, Yan P, Benson DM, Byrd JC, Baiocchi R, Kaur B, Hofmeister CC, Pichiorri F

Mol Cancer Ther 15 830-41 05/01/2016
Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma.

Stiff A, Caserta E, Sborov DW, Nuovo GJ, Mo X, Schlotter SY, Canella A, Smith E, Badway J, Old M, Jaime-Ramirez AC, Yan P, Benson DM, Byrd JC, Baiocchi R, Kaur B, Hofmeister CC, Pichiorri F, Stiff A, Caserta E, Sborov DW, Nuovo GJ, Mo X, Schlotter SY, Canella A, Smith E, Badway J, Old M, Jaime-Ramirez AC, Yan P, Benson DM Jr, Byrd JC, Baiocchi R, Kaur B, Hofmeister CC, Pichiorri F, Stiff A, Caserta E, Sborov DW, Nuovo GJ, Mo X, Schlotter SY, Canella A, Smith E, Badway J, Old M, Jaime-Ramirez AC, Yan P, Benson DM, Byrd JC, Baiocchi R, Kaur B, Hofmeister CC, Pichiorri F

Mol Cancer Ther 15 830-41 05/01/2016
Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.

Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, Donnell LO, Bradbury H, Kitzler R, Andritsos L, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Benson D, Muthusamy N, Lozanski G, Devine S, Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, Donnell LO, Bradbury H, Kitzler R, Andritsos L, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Benson DM, Muthusamy N, Lozanski G, Devine SM

Biol Blood Marrow Transplant 22 658-68 04/01/2016
Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.

Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, Donnell LO, Bradbury H, Kitzler R, Andritsos L, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Benson D, Muthusamy N, Lozanski G, Devine S, Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, Donnell LO, Bradbury H, Kitzler R, Andritsos L, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Benson DM, Muthusamy N, Lozanski G, Devine SM

Biol Blood Marrow Transplant 22 658-68 04/01/2016
Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers.

Harshman SW, Canella A, Ciarlariello PD, Agarwal K, Branson OE, Rocci A, Cordero H, Phelps MA, Hade EM, Dubovsky JA, Palumbo A, Rosko A, Byrd JC, Hofmeister CC, Benson DM, Paulaitis ME, Freitas MA, Pichiorri F, Harshman SW, Canella A, Ciarlariello PD, Agarwal K, Branson OE, Rocci A, Cordero H, Phelps MA, Hade EM, Dubovsky JA, Palumbo A, Rosko A, Byrd JC, Hofmeister CC, Benson DM Jr, Paulaitis ME, Freitas MA, Pichiorri F

J Proteomics 136 89-98 03/16/2016
Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers.

Harshman SW, Canella A, Ciarlariello PD, Agarwal K, Branson OE, Rocci A, Cordero H, Phelps MA, Hade EM, Dubovsky JA, Palumbo A, Rosko A, Byrd JC, Hofmeister CC, Benson DM, Paulaitis ME, Freitas MA, Pichiorri F, Harshman SW, Canella A, Ciarlariello PD, Agarwal K, Branson OE, Rocci A, Cordero H, Phelps MA, Hade EM, Dubovsky JA, Palumbo A, Rosko A, Byrd JC, Hofmeister CC, Benson DM Jr, Paulaitis ME, Freitas MA, Pichiorri F

J Proteomics 136 89-98 03/16/2016
Tocilizumab for steroid refractory acute graft-versus-host disease.

Roddy JV, Haverkos BM, McBride A, Leininger KM, Jaglowski S, Penza S, Klisovic R, Blum W, Vasu S, Hofmeister CC, Benson DM, Andritsos LA, Devine SM, Efebera YA

Leuk Lymphoma 57 81-5 01/01/2016
Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT).

Efebera YA, Geyer S, Andritsos L, Vasu S, Jaglowski S, Bingman A, Blum W, Klisovic R, Hofmeister CC, Benson DM, Penza S, Elder P, Cortright K, Kitzler R, Coombes K, O'Donnell L, Daneault B, Bradbury H, Zhang J, Chen X, Garman S, Ranganathan P, Yu X, Hofstetter J, Yu J, Garzon R, Scrape SR, Lozanski G, Devine SM

Biol Blood Marrow Transplant 22 71-9 01/01/2016
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials.

Kohrt HE, Tumeh PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, Kirsch I, Kleen T, Kroemer G, Lanier L, Levy R, Lyerly HK, Maecker H, Marabelle A, Melenhorst J, Miller J, Melero I, Odunsi K, Palucka K, Peoples G, Ribas A, Robins H, Robinson W, Serafini T, Sondel P, Vivier E, Weber J, Wolchok J, Zitvogel L, Disis ML, Cheever MA, Cancer Immunotherapy Trials Network (CITN)

J Immunother Cancer 4 15 01/01/2016
Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma.

Sborov DW, Benson DM, Williams N, Huang Y, Bowers MA, Humphries K, Efebera Y, Devine S, Hofmeister CC

Br J Haematol 171 74-83 10/01/2015
Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma.

Rosko A, Hofmeister C, Benson D, Efebera Y, Huang Y, Gillahan J, Byrd JC, Burd CE

Bone Marrow Transplant 50 1379-81 10/01/2015
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.

Benson DM, Cohen AD, Jagannath S, Munshi NC, Spitzer G, Hofmeister CC, Efebera YA, Andre P, Zerbib R, Caligiuri MA, Benson DM Jr, Cohen AD, Jagannath S, Munshi NC, Spitzer G, Hofmeister CC, Efebera YA, Andre P, Zerbib R, Caligiuri MA

Clin Cancer Res 21 4055-61 09/15/2015
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.

Benson DM, Cohen AD, Jagannath S, Munshi NC, Spitzer G, Hofmeister CC, Efebera YA, Andre P, Zerbib R, Caligiuri MA, Benson DM Jr, Cohen AD, Jagannath S, Munshi NC, Spitzer G, Hofmeister CC, Efebera YA, Andre P, Zerbib R, Caligiuri MA

Clin Cancer Res 21 4055-61 09/15/2015
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.

Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA, Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM Jr, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA

Br J Haematol 169 701-10 06/01/2015
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.

Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA, Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM Jr, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA

Br J Haematol 169 701-10 06/01/2015
Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant.

Salem G, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos L, Klisovic R, Vasu S, Blum W, Devine SM, Jaglowski S, Efebera YA

Leuk Lymphoma 56 1058-65 04/01/2015
A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma.

Hofmeister CC, Williams N, Geyer S, Hade EM, Bowers MA, Earl CT, Vaughn J, Bingman A, Humphries K, Lozanski G, Baiocchi RA, Jaglowski SM, Blum K, Porcu P, Flynn J, Penza S, Benson DM, Andritsos LA, Devine SM

Leuk Lymphoma 56 1043-9 04/01/2015
A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma.

Sborov DW, Nuovo GJ, Stiff A, Mace TA, Lesinski GB, Benson DM, Efebera YA, Rosko AE, Pichiorri F, Grever MR, Hofmeister CC, Sborov DW, Nuovo GJ, Stiff A, Mace T, Lesinski GB, Benson DM Jr, Efebera YA, Rosko AE, Pichiorri F, Grever MR, Hofmeister CC

Clin Cancer Res 20 5946-55 12/01/2014
A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma.

Sborov DW, Nuovo GJ, Stiff A, Mace TA, Lesinski GB, Benson DM, Efebera YA, Rosko AE, Pichiorri F, Grever MR, Hofmeister CC, Sborov DW, Nuovo GJ, Stiff A, Mace T, Lesinski GB, Benson DM Jr, Efebera YA, Rosko AE, Pichiorri F, Grever MR, Hofmeister CC

Clin Cancer Res 20 5946-55 12/01/2014
Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study.

Bechtel T, McBride A, Crawford B, Bullington S, Hofmeister CC, Benson DM Jr, Jaglowski S, Penza S, Andritsos LA, Devine SM

Support Care Cancer 22 2911-6 11/01/2014
The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma.

Jaglowski SM, Ruppert AS, Hofmeister CC, Elder P, Blum W, Klisovic R, Vasu S, Penza S, Efebera YA, Benson DM Jr, Devine SM, Andritsos LA

Bone Marrow Transplant 49 1323-9 10/01/2014
Circulating miRNA markers show promise as new prognosticators for multiple myeloma.

Rocci A, Hofmeister CC, Geyer S, Stiff A, Gambella M, Cascione L, Guan J, Benson DM, Efebera YA, Talabere T, Dirisala V, Smith EM, Omedè P, Isaia G, De Luca L, Rossi D, Gentili S, Uccello G, Consiglio J, Ria R, Benevolo G, Bringhen S, Callea V, Weiss B, Ferro A, Magarotto V, Alder H, Byrd JC, Boccadoro M, Marcucci G, Palumbo A, Pichiorri F

Leukemia 28 1922-6 09/01/2014
The transcription Factor AHR prevents the differentiation of a stage 3 innate lymphoid cell subset to natural killer cells.

Hughes T, Briercheck EL, Freud AG, Trotta R, McClory S, Scoville SD, Keller K, Deng Y, Cole J, Harrison N, Mao C, Zhang J, Benson DM, Yu J, Caligiuri MA

Cell Rep 8 150-62 07/10/2014
Novel gelsolin variant as the cause of nephrotic syndrome and renal amyloidosis in a large kindred.

Sturm A, Baack EC, Hofmeister CC, Satoskar A, Nadasdy T, Nadasdy G, Benson DM, Gillmore JD, Hawkins PN, Rowczenio D, Efebera YA

Amyloid 21 110-2 06/01/2014
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110d, for relapsed/refractory chronic lymphocytic leukemia.

Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, Ulrich RG, Yu AS, Miller LL, Furman RR

Blood 123 3390-7 05/29/2014
A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).

Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, Benson DM, Byrd JC, Peterman S, Cho Y, Yu A, Godfrey WR, Wagner-Johnston ND

Blood 123 3398-405 05/29/2014
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-d, as therapy for previously treated indolent non-Hodgkin lymphoma.

Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, Cho Y, Webb HK, Johnson DM, Yu AS, Ulrich RG, Godfrey WR, Miller LL, Spurgeon SE

Blood 123 3406-13 05/29/2014
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.

Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K, He X, Devine SM, Zhang X, Caligiuri MA, Hofmeister CC, Yu J

Leukemia 28 917-27 04/01/2014
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.

Kolitz JE, George SL, Benson DM Jr, Maharry K, Marcucci G, Vij R, Powell BL, Allen SL, Deangelo DJ, Shea TC, Stock W, Bakan CE, Hars V, Hoke E, Bloomfield CD, Caligiuri MA, Larson RA, Alliance for Clinical Trials in Oncology

Cancer 120 1010-7 04/01/2014
Killer immunoglobulin-like receptors and tumor immunity.

Benson DM Jr, Caligiuri MA

Cancer Immunol Res 2 99-104 02/01/2014
A phase I trial of flavopiridol in relapsed multiple myeloma.

Hofmeister CC, Poi M, Bowers MA, Zhao W, Phelps MA, Benson DM, Kraut EH, Farag S, Efebera YA, Sexton J, Lin TS, Grever M, Byrd JC

Cancer Chemother Pharmacol 73 249-57 02/01/2014
Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma.

Jones JA, Rupert AS, Poi M, Phelps MA, Andritsos L, Baiocchi R, Benson DM, Blum KA, Christian B, Flynn J, Penza S, Porcu P, Grever MR, Byrd JC

Am J Hematol 89 19-24 01/01/2014
Aldehyde dehydrogenase-1a1 induces oncogene suppressor genes in B cell populations.

Yasmeen R, Meyers JM, Alvarez CE, Thomas JL, Bonnegarde-Bernard A, Alder H, Papenfuss TL, Benson DM Jr, Boyaka PN, Ziouzenkova O

Biochim Biophys Acta 1833 3218-27 12/01/2013
Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.

Hofmeister CC, Efebera YA, Kwon H, Starling GC, Ciarlariello D, Bhaskar S, Briercheck EL, Hughes T, Yu J, Rice A, Benson DM Jr, Collins SM, Bakan CE, Swartzel GD, Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, Starling GC, Ciarlariello D, Bhaskar S, Briercheck EL, Hughes T, Yu J, Rice A, Benson DM Jr

Cancer Immunol Immunother 62 1841-9 12/01/2013
Characterization of multiple myeloma vesicles by label-free relative quantitation.

Harshman SW, Canella A, Ciarlariello PD, Rocci A, Agarwal K, Smith EM, Talabere T, Efebera YA, Hofmeister CC, Benson DM Jr, Paulaitis ME, Freitas MA, Pichiorri F

Proteomics 13 3013-29 10/01/2013